Abstract

PBRM1 is a novel tumor suppressor gene that can inhibit cancer cell proliferation and predict the outcome of renal cell carcinoma (RCC), but its biological role needs further elucidation. We examined expression of the PBRM1 gene in RCC cell lines and the effect of PBRM1 on cell proliferation and cell cycle in RCC ACHN cells. Microarray processing and analysis was used to explore novel pathways involved in tumorigenesis related to PBRM1 knockdown. PBRM1 was expressed at high levels in RCC ACHN cells and lentivirus-mediated PBRM1 knockdown in these cells caused an increase in the proportion of cells in S phase of the cell cycle and promoted in vitro proliferation and migration. In vivo experiments showed that downregulation of PBRM1 promoted tumorigenesis in nude mice. In pathway gene chip analysis, the chemokine/chemokine receptor interaction pathway showed the greatest difference in gene expression upon PBRM1 knockdown. Protein levels of IL6ST and CCL2 were increased, whereas levels of interleukin (IL)-8, IL-6, and CXCL2 were decreased, in knockdown cells. Re-expression of IL-8 in PBRM1 knockdown ACHN cells could significantly decrease cell proliferation/migration and induced cell arrest in the G2/M phase. These findings indicate that PBRM1 alters cell cycle progression and inhibits proliferation and migration of ACHN cells through the chemokine/chemokine receptor pathway.

Highlights

  • Renal cell carcinoma (RCC) is the most common type of cancer in the kidney and accounts for approximately 3% of all adult malignancies[1]

  • In this study we investigate the expression and function of PBRM1 in clear cell RCC (ccRCC) cells in vitro and in vivo, and present data suggesting that PBRM1 may be a regulator of chemokine/chemokine receptor pathways

  • We knocked down PBRM1 in ACHN RCC cells using three different PBRM1 RNAi sequences to study the biological functions of PBRM1

Read more

Summary

Introduction

Renal cell carcinoma (RCC) is the most common type of cancer in the kidney and accounts for approximately 3% of all adult malignancies[1]. Among RCCs, clear cell RCC (ccRCC) is the most common subtype, accounting for approximately 70%–75% of cases[2], and is more likely to present with advanced T stage, metastatic disease, and higher grade[3]. Alteration in the von Hippel-Lindau (VHL) gene is the hallmark of ccRCC; inactivation of VHL has not been found to consistently correlate with prognostic features of ccRCC[4]. Exome sequencing has unveiled additional genes that are mutated in ccRCC, including. PBRM1 and chemokine pathways in kidney cancer. PBRM1, BAP1, and SETD2[5]. As the second most frequently mutated gene after VHL, the role of PBRM1 in ccRCC tumorigenesis is of great interest

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call